Main general features of a series of 80 patients with refractory uveitis due to immune-mediated inflammatory diseases (IMID) treated with certolizumab pegol (CZP)
| No. of patients/eyes affected, n/n | 80/111 |
| Age, mean (SD), years | 41.6±11.7 |
| Sex, male/female, n/n (%) | 33/47 (41.2/58.8) |
| Time between IMID diagnosis and CZP initiation, median (IQR) | 72 (35–144) |
| Patients initiating CZP due to pregnancy, n (%) | 20 (25) |
| Underlying IMID, n (%) | |
| Spondyloarthritis | 43 (53.7) |
| Behçet’s disease | 10 (12.5) |
| Psoriatic arthritis | 8 (10) |
| Crohn’s disease | 4 (5) |
| Sarcoidosis | 2 (2.5) |
| Juvenile idiopathic arthritis | 1 (1.3) |
| Reactive arthritis | 1 (1.3) |
| Rheumatoid arthritis | 1 (1.3) |
| Relapsing polychondritis | 1 (1.3) |
| TINU | 1 (1.3) |
| Pars planitis | 1 (1.3) |
| Birdshot choroidopathy | 1 (1.3) |
| Idiopathic uveitis | 6 (7.5) |
| Ocular parameters at CZP initiation | |
| AC cells count, median (IQR) | 1 [1.0–1.75) |
| Patients who present vitritis, n (%) | 14 (17.5) |
| BCVA, mean (SD) | 0.68±0.27 |
| OCT, mean (SD) | 297.48±48.19 |
| Patients who present retinal vasculitis, n (%) | 3 (3.8) |
| Uveitis pattern, n (%) | |
| Bilateral/Unilateral | 31/49 (38.7/61.3) |
| Anterior | 61 (76.3) |
| Intermediate | 4 (5.0) |
| Posterior | 7 (8.8) |
| Panuveitis | 7 (8.8) |
BCVA, best-corrected visual acuity; OCT, optical coherence tomography.